CN115066241A - 用于治疗实体瘤的组合物 - Google Patents

用于治疗实体瘤的组合物 Download PDF

Info

Publication number
CN115066241A
CN115066241A CN202080078495.3A CN202080078495A CN115066241A CN 115066241 A CN115066241 A CN 115066241A CN 202080078495 A CN202080078495 A CN 202080078495A CN 115066241 A CN115066241 A CN 115066241A
Authority
CN
China
Prior art keywords
pharmaceutical composition
group
weight
alkyl
composition comprises
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN202080078495.3A
Other languages
English (en)
Chinese (zh)
Inventor
艾伦·布鲁门菲尔德
拉凯利·盖塔
伊兰·布劳格伦德
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Rachel Therapeutics Ltd
Original Assignee
Rachel Therapeutics Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Rachel Therapeutics Ltd filed Critical Rachel Therapeutics Ltd
Publication of CN115066241A publication Critical patent/CN115066241A/zh
Pending legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Dermatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
CN202080078495.3A 2019-09-15 2020-09-14 用于治疗实体瘤的组合物 Pending CN115066241A (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201962900557P 2019-09-15 2019-09-15
US62/900,557 2019-09-15
PCT/IB2020/000745 WO2021048626A1 (en) 2019-09-15 2020-09-14 Compositions for the treatment of solid tumors

Publications (1)

Publication Number Publication Date
CN115066241A true CN115066241A (zh) 2022-09-16

Family

ID=74866186

Family Applications (1)

Application Number Title Priority Date Filing Date
CN202080078495.3A Pending CN115066241A (zh) 2019-09-15 2020-09-14 用于治疗实体瘤的组合物

Country Status (7)

Country Link
US (1) US20220323411A1 (https=)
EP (1) EP4031130A4 (https=)
JP (1) JP7822308B2 (https=)
CN (1) CN115066241A (https=)
AU (1) AU2020347539A1 (https=)
IL (1) IL291351A (https=)
WO (1) WO2021048626A1 (https=)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3307323B1 (en) 2015-06-15 2022-07-13 Raziel Therapeutics Ltd. Carbazole derivatives for the treatment of fibrotic diseases and related symptoms, and conditions thereof
EP4334286A4 (en) * 2021-05-06 2025-03-19 Raziel Therapeutics Ltd. CRYSTALLINE CARBAZOLE DERIVATIVE
CN120693158A (zh) * 2022-11-07 2025-09-23 拉结尔治疗有限公司 结晶咔唑衍生物及其制备方法

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20110305661A1 (en) * 2008-10-06 2011-12-15 John Tucker Carbazole Compounds and Therapeutic Uses of the Compounds
CN104010636A (zh) * 2011-11-15 2014-08-27 耶路撒冷希伯来大学伊森姆研究发展有限公司 三环化合物、包含它们的组合物及其用途
US20180169066A1 (en) * 2015-06-15 2018-06-21 Raziel Therapeutics Ltd. Carbazole derivatives for the treatment of fibrotic diseases and related symptoms, and conditions thereof

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0311406D0 (en) * 2003-05-17 2003-06-25 Queen Mary & Westfield College Substituted phosphonate fluorescent sensors,and use thereof
US20230089484A1 (en) 2020-01-28 2023-03-23 Raziel Therapeutics Ltd. Compositions for the treatment of angiolipoma

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20110305661A1 (en) * 2008-10-06 2011-12-15 John Tucker Carbazole Compounds and Therapeutic Uses of the Compounds
CN104010636A (zh) * 2011-11-15 2014-08-27 耶路撒冷希伯来大学伊森姆研究发展有限公司 三环化合物、包含它们的组合物及其用途
US20180169066A1 (en) * 2015-06-15 2018-06-21 Raziel Therapeutics Ltd. Carbazole derivatives for the treatment of fibrotic diseases and related symptoms, and conditions thereof

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
C. BROOKE STEELE，等: "Vital Signs: Trends in Incidence of Cancers Associated with Overweight and Obesity-United States, 2005-2014", MORBIDITY AND MORTALITY WEEKLY REPORT, vol. 66, no. 39, 3 October 2017 (2017-10-03), pages 1052 *
LAN-XIANG LIU，等: "Synthesis and antitumor activity of novel N-substituted carbazole imidazolium salt derivatives", SCIENTIFIC REPORTS, vol. 05, 19 August 2015 (2015-08-19), pages 1 - 20 *

Also Published As

Publication number Publication date
EP4031130A1 (en) 2022-07-27
AU2020347539A1 (en) 2022-03-31
JP2023503769A (ja) 2023-02-01
IL291351A (en) 2022-05-01
EP4031130A4 (en) 2023-10-11
WO2021048626A1 (en) 2021-03-18
US20220323411A1 (en) 2022-10-13
JP7822308B2 (ja) 2026-03-02

Similar Documents

Publication Publication Date Title
JP7822308B2 (ja) 固形腫瘍の処置のための組成物
CN115335047B (zh) 用于治疗血管脂肪瘤的组合物
KR20100051829A (ko) 인산화된 피론 유사체 및 방법
TW202432558A (zh) 一種噠嗪稠芳環化合物及其用途
KR19980081621A (ko) 과민성 장 증후군의 증상을 치료하기 위한 엔케이-1 수용체 길항물질
US20180318304A1 (en) Methods of Using BTK Inhibitors to Treat Dermatoses
ES2928666T3 (es) Piridinetionas, sus composiciones farmacéuticas y su uso terapéutico para el tratamiento de enfermedades proliferativas, inflamatorias, neurodegenerativas o inmunomediadas
US12264152B2 (en) Certain chemical compositions and methods of use thereof
HK40077772A (en) Compositions for the treatment of solid tumors
US20230355584A1 (en) Compositions and methods for the treatment of lipid-related disorders
WO2022058792A1 (en) Compositions for the treatment of fat related conditions and disorders
US20240335424A1 (en) Compositions and methods for treating lipoma pain
US20210221817A1 (en) Novel heteroaromatic compounds as potent modulators of the hippo-yap signaling pathway lats1/2 kinases

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
REG Reference to a national code

Ref country code: HK

Ref legal event code: DE

Ref document number: 40077772

Country of ref document: HK